{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:37Z","timestamp":1791323677644,"version":"4.3.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69060-5","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:36:36Z","timestamp":1770078996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel"],"prefix":"10.1038","volume":"17","author":[{"given":"Yuqi","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-4027","authenticated-orcid":false,"given":"Ruiqi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-7116","authenticated-orcid":false,"given":"Yunfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-7985","authenticated-orcid":false,"given":"Hongnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-0899","authenticated-orcid":false,"given":"Hongquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-840X","authenticated-orcid":false,"given":"Jun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"69060_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt, B., Peterse, J. L. & van \u2018t Veer, L. J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591\u2013602 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"69060_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaoncol.2019.3876","volume":"6","author":"T Mukama","year":"2020","unstructured":"Mukama, T. et al. Risk-adapted starting age of screening for relatives of patients with breast cancer. JAMA Oncol. 6, 68\u201374 (2020).","journal-title":"JAMA Oncol."},{"key":"69060_CR3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1056\/NEJMcibr1711545","volume":"377","author":"A DeMichele","year":"2017","unstructured":"DeMichele, A., Yee, D. & Esserman, L. Mechanisms of resistance to neoadjuvant chemotherapy in breast cancer. N Engl. J. Med. 377, 2287\u20132289 (2017).","journal-title":"N Engl. J. Med."},{"key":"69060_CR4","doi-asserted-by":"publisher","first-page":"732047","DOI":"10.1155\/2013\/732047","volume":"2013","author":"SP Gampenrieder","year":"2013","unstructured":"Gampenrieder, S. P., Rinnerthaler, G. & Greil, R. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J. Oncol. 2013, 732047 (2013).","journal-title":"J. Oncol."},{"key":"69060_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/14656566.2012.651127","volume":"13","author":"V Guarneri","year":"2012","unstructured":"Guarneri, V., Dieci, M. V. & Conte, P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin. Pharmacother. 13, 395\u2013406 (2012).","journal-title":"Expert Opin. Pharmacother."},{"key":"69060_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/ecp.11.7","volume":"4","author":"AJ Montero","year":"2011","unstructured":"Montero, A. J., Adams, B., Diaz-Montero, C. M. & Gluck, S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev. Clin. Pharmacol. 4, 329\u2013334 (2011).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"69060_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40164-017-0066-5","volume":"6","author":"A Brufsky","year":"2017","unstructured":"Brufsky, A. nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Exp. Hematol. Oncol. 6, 7 (2017).","journal-title":"Exp. Hematol. Oncol."},{"key":"69060_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell 43, 446\u2013463 (2025).","journal-title":"Cancer Cell"},{"key":"69060_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41556-018-0256-3","volume":"21","author":"I Keklikoglou","year":"2019","unstructured":"Keklikoglou, I. et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat. Cell Biol. 21, 190\u2013202 (2019).","journal-title":"Nat. Cell Biol."},{"key":"69060_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457\u2013474 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"69060_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccr.2005.08.002","volume":"8","author":"M De Palma","year":"2005","unstructured":"De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211\u2013226 (2005).","journal-title":"Cancer Cell"},{"key":"69060_CR12","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1158\/0008-5472.CAN-11-0627","volume":"71","author":"LG Daenen","year":"2011","unstructured":"Daenen, L. G. et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res. 71, 6976\u20136985 (2011).","journal-title":"Cancer Res."},{"key":"69060_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0026","volume":"9","author":"GS Karagiannis","year":"2017","unstructured":"Karagiannis, G. S. et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci. Transl. Med. 9, eaan0026 (2017).","journal-title":"Sci. Transl. Med."},{"key":"69060_CR14","doi-asserted-by":"publisher","first-page":"E7159","DOI":"10.1073\/pnas.1700455114","volume":"114","author":"YS Chang","year":"2017","unstructured":"Chang, Y. S., Jalgaonkar, S. P., Middleton, J. D. & Hai, T. Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc. Natl. Acad. Sci. USA 114, E7159\u2013E7168 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69060_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora, M. et al. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell 182, 886\u2013900 (2020).","journal-title":"Cell"},{"key":"69060_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2024.05.001","volume":"42","author":"J Zhong","year":"2024","unstructured":"Zhong, J. et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer Cell 42, 968\u2013984 e9 (2024).","journal-title":"Cancer Cell"},{"key":"69060_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/gutjnl-2019-319227","volume":"70","author":"A Esparza-Baquer","year":"2021","unstructured":"Esparza-Baquer, A. et al. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut 70, 1345\u20131361 (2021).","journal-title":"Gut"},{"key":"69060_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","volume":"24","author":"MD Park","year":"2023","unstructured":"Park, M. D. et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat. Immunol. 24, 792\u2013801 (2023).","journal-title":"Nat. Immunol."},{"key":"69060_CR19","doi-asserted-by":"crossref","unstructured":"Yofe, I. et al. Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary. Cancer Discov. 13, 2610\u20132631 (2023).","DOI":"10.1158\/2159-8290.CD-23-0299"},{"key":"69060_CR20","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593 (2021).","journal-title":"Cancer Cell"},{"key":"69060_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/ol.2024.14642","volume":"28","author":"H Lv","year":"2024","unstructured":"Lv, H. et al. Efficacy and safety of nanoparticle albumin\u2011bound paclitaxel compared with solvent\u2011based paclitaxel in adjuvant therapy for breast cancer: A retrospective study. Oncol. Lett. 28, 509 (2024).","journal-title":"Oncol. Lett."},{"key":"69060_CR22","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","volume":"33","author":"HS Rugo","year":"2015","unstructured":"Rugo, H. S. et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound Nab-Paclitaxel once per week or Ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502\/NCCTG N063H (Alliance). J. Clin. Oncol. 33, 2361\u20132369 (2015).","journal-title":"J. Clin. Oncol."},{"key":"69060_CR23","doi-asserted-by":"publisher","first-page":"GS3-06","DOI":"10.1158\/1538-7445.SABCS17-GS3-06","volume":"78","author":"H Rugo","year":"2018","unstructured":"Rugo, H. et al. Abstract GS3-06: Long-term follow-up of CALGB 40502\/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +\/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Cancer Res. 78, GS3-06 (2018).","journal-title":"Cancer Res."},{"key":"69060_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.annonc.2021.01.065","volume":"32","author":"A Brufsky","year":"2021","unstructured":"Brufsky, A. et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Ann. Oncol. 32, 652\u2013660 (2021).","journal-title":"Ann. Oncol."},{"key":"69060_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2217\/cer-2019-0077","volume":"8","author":"P Luhn","year":"2019","unstructured":"Luhn, P. et al. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. J. Comp. Eff. Res. 8, 1173\u20131185 (2019).","journal-title":"J. Comp. Eff. Res."},{"key":"69060_CR26","first-page":"681","volume":"25","author":"X Han","year":"2020","unstructured":"Han, X. & Wang, Z. Efficacy of albumin-bound paclitaxel in the treatment of advanced refractory breast cancer and its effect on serum resistin. J. Buon 25, 681\u2013687 (2020).","journal-title":"J. Buon"},{"key":"69060_CR27","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1200\/JCO.18.01842","volume":"37","author":"M Untch","year":"2019","unstructured":"Untch, M. et al. NAB-Paclitaxel improves disease-free survival in early breast cancer: GBG 69-geparSepto. J. Clin. Oncol. 37, 2226\u20132234 (2019).","journal-title":"J. Clin. Oncol."},{"key":"69060_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles, D. et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol. 32, 1245\u20131255 (2021).","journal-title":"Ann. Oncol."},{"key":"69060_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/annonc\/mdz061","volume":"30","author":"T Bachelot","year":"2019","unstructured":"Bachelot, T. et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann. Oncol. 30, 766\u2013773 (2019).","journal-title":"Ann. Oncol."},{"key":"69060_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/annonc\/mdw610","volume":"28","author":"S Loibl","year":"2017","unstructured":"Loibl, S. et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann. Oncol. 28, 497\u2013504 (2017).","journal-title":"Ann. Oncol."},{"key":"69060_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","volume":"17","author":"M Untch","year":"2016","unstructured":"Untch, M. et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 17, 345\u2013356 (2016).","journal-title":"Lancet Oncol."},{"key":"69060_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10549-016-3736-9","volume":"156","author":"MM Jain","year":"2016","unstructured":"Jain, M. M. et al. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II\/III study. Breast Cancer Res. Treat. 156, 125\u2013134 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"69060_CR33","doi-asserted-by":"publisher","first-page":"CT049","DOI":"10.1158\/1538-7445.AM2019-CT049","volume":"79","author":"P Schmid","year":"2019","unstructured":"Schmid, P. et al. Phase Ib study evaluating a triplet combination of ipatasertib (IPAT) atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced\/metastatic triple-negative breast cancer (TNBC). Cancer Res. 79, CT049 (2019).","journal-title":"Cancer Res."},{"key":"69060_CR34","doi-asserted-by":"crossref","first-page":"PS12","DOI":"10.1158\/1538-7445.AM2021-NG12","volume":"81","author":"P Schmid","year":"2021","unstructured":"Schmid, P. et al. Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced\/metastatic triple-negative breast cancer (TNBC). Cancer Res. 81, PS12\u2013PS28 (2021).","journal-title":"Cancer Res."},{"key":"69060_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1078-0432.CCR-23-2084","volume":"30","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clin. Cancer Res. 30, 767\u2013778 (2024).","journal-title":"Clin. Cancer Res."},{"key":"69060_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1743-7563.2009.01235.x","volume":"5","author":"ZZ Guan","year":"2009","unstructured":"Guan, Z. Z. et al. Superior efficacy of a cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in chinese patients with metastatic breast cancer. Asia Pac. J. Clin. Oncol. 5, 165\u2013174 (2009).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"69060_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","volume":"4","author":"L Gianni","year":"2018","unstructured":"Gianni, L. et al. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 4, 302\u2013308 (2018).","journal-title":"JAMA Oncol."},{"key":"69060_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2023.102707","volume":"54","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer. Nanomedicine 54, 102707 (2023).","journal-title":"Nanomedicine"},{"key":"69060_CR39","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/nnm-2018-0485","volume":"14","author":"F Xie","year":"2019","unstructured":"Xie, F. et al. Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer. Nanomedicine 14, 1595\u20131603 (2019).","journal-title":"Nanomedicine"},{"key":"69060_CR40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.annonc.2023.04.002","volume":"34","author":"O Gluz","year":"2023","unstructured":"Gluz, O. et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+\/HER2\u2212 early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+\/HER2\u2212 trial. Ann. Oncol. 34, 531\u2013542 (2023).","journal-title":"Ann. Oncol."},{"key":"69060_CR41","first-page":"1969","volume":"10","author":"L Huang","year":"2015","unstructured":"Huang, L. et al. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int. J. Nanomed. 10, 1969\u20131975 (2015).","journal-title":"Int. J. Nanomed."},{"key":"69060_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2023.102666","volume":"49","author":"W Shi","year":"2023","unstructured":"Shi, W. et al. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer. Nanomedicine 49, 102666 (2023).","journal-title":"Nanomedicine"},{"key":"69060_CR43","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar, W. J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794\u20137803 (2005).","journal-title":"J. Clin. Oncol."},{"key":"69060_CR44","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen, E. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparSixto randomized clinical trial. JAMA Oncol. 3, 1378\u20131385 (2017).","journal-title":"JAMA Oncol."},{"key":"69060_CR45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","volume":"6","author":"E Pohl-Rescigno","year":"2020","unstructured":"Pohl-Rescigno, E. et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the geparOcto randomized clinical trial. JAMA Oncol. 6, 744\u2013748 (2020).","journal-title":"JAMA Oncol."},{"key":"69060_CR46","first-page":"480","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert, L. A., Gumusay, O., Idossa, D. & Rugo, H. S. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J. Clin. 73, 480\u2013515 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"69060_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02259-4","volume":"41","author":"I Akrida","year":"2023","unstructured":"Akrida, I. et al. Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors. Med. Oncol. 41, 20 (2023).","journal-title":"Med. Oncol."},{"key":"69060_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cells9020418","volume":"9","author":"S Donzelli","year":"2020","unstructured":"Donzelli, S. et al. Paracrine signaling from breast cancer cells causes activation of ID4 expression in tumor-associated macrophages. Cells 9, 418 (2020).","journal-title":"Cells"},{"key":"69060_CR49","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2024.03.009","volume":"42","author":"M Liu","year":"2024","unstructured":"Liu, M. et al. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer Cell 42, 885\u2013903 (2024).","journal-title":"Cancer Cell"},{"key":"69060_CR50","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41418-024-01292-8","volume":"31","author":"D Li","year":"2024","unstructured":"Li, D. et al. IFI35 regulates non-canonical NF-kappaB signaling to maintain glioblastoma stem cells and recruit tumor-associated macrophages. Cell Death Differ. 31, 738\u2013752 (2024).","journal-title":"Cell Death Differ."},{"key":"69060_CR51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","volume":"41","author":"A Mousset","year":"2023","unstructured":"Mousset, A. et al. Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-beta activation. Cancer Cell 41, 757\u2013775 (2023).","journal-title":"Cancer Cell"},{"key":"69060_CR52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ccell.2020.12.012","volume":"39","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell 39, 423\u2013437 (2021).","journal-title":"Cancer Cell"},{"key":"69060_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157399","volume":"132","author":"M Qi","year":"2022","unstructured":"Qi, M. et al. Targeting FAPalpha-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models. J. Clin. Invest. 132, e157399 (2022).","journal-title":"J. Clin. Invest."},{"key":"69060_CR54","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.18632\/aging.102831","volume":"12","author":"S Tian","year":"2020","unstructured":"Tian, S. et al. SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt\/beta-catenin signaling pathway. Aging 12, 3574\u20133593 (2020).","journal-title":"Aging"},{"key":"69060_CR55","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","volume":"40","author":"J Fu","year":"2021","unstructured":"Fu, J. et al. HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 40, 4625\u20134651 (2021).","journal-title":"Oncogene"},{"key":"69060_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237\u2013253 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69060_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc2511","volume":"7","author":"J Hu","year":"2021","unstructured":"Hu, J. et al. Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme. Sci. Adv. 7, eabc2511 (2021).","journal-title":"Sci. Adv."},{"key":"69060_CR58","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. nab-Paclitaxel mechanisms of action and delivery. J. Control Release 170, 365\u2013372 (2013).","journal-title":"J. Control Release"},{"key":"69060_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1593\/tlo.09109","volume":"2","author":"N Desai","year":"2009","unstructured":"Desai, N., Trieu, V., Damascelli, B. & Soon-Shiong, P. SPARC Expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2, 59\u201364 (2009).","journal-title":"Transl. Oncol."},{"key":"69060_CR60","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai, N. et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317\u20131324 (2006).","journal-title":"Clin. Cancer Res."},{"key":"69060_CR61","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872\u20132878 (2018).","journal-title":"J. Clin. Oncol."},{"key":"69060_CR62","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.21037\/tlcr.2019.06.06","volume":"8","author":"M Jove","year":"2019","unstructured":"Jove, M., Vilarino, N. & Nadal, E. Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer. Transl. Lung Cancer Res. 8, S364\u2013S368 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"69060_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/srep23002","volume":"6","author":"MJ Olnes","year":"2016","unstructured":"Olnes, M. J. et al. Effects of Systemically Administered Hydrocortisone on the Human Immunome. Sci. Rep. 6, 23002 (2016).","journal-title":"Sci. Rep."},{"key":"69060_CR64","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-14-0969","volume":"14","author":"T Voloshin","year":"2015","unstructured":"Voloshin, T. et al. Blocking IL1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol. Cancer Ther. 14, 1385\u20131394 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"69060_CR65","doi-asserted-by":"publisher","first-page":"984193","DOI":"10.3389\/fonc.2022.984193","volume":"12","author":"EM Wolf","year":"2022","unstructured":"Wolf, E. M., Fingleton, B. & Hasty, A. H. The therapeutic potential of TREM2 in cancer. Front. Oncol. 12, 984193 (2022).","journal-title":"Front. Oncol."},{"key":"69060_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06756-w","volume":"15","author":"Y Cui","year":"2024","unstructured":"Cui, Y. et al. TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway in mice. Cell Death Dis. 15, 401 (2024).","journal-title":"Cell Death Dis."},{"key":"69060_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02481-5","volume":"9","author":"N Linde","year":"2018","unstructured":"Linde, N. et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat. Commun. 9, 21 (2018).","journal-title":"Nat. Commun."},{"key":"69060_CR68","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1172\/JCI91561","volume":"127","author":"NM Ratnam","year":"2017","unstructured":"Ratnam, N. M. et al. NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127, 3796\u20133809 (2017).","journal-title":"J. Clin. Invest."},{"key":"69060_CR69","doi-asserted-by":"publisher","unstructured":"Moher, D. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 4, https:\/\/doi.org\/10.1186\/2046-4053-4-1 (2015).","DOI":"10.1186\/2046-4053-4-1"},{"key":"69060_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK Lo","year":"2014","unstructured":"Lo, C. K., Mertz, D. & Loeb, M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med. Res. Methodol. 14, 45 (2014).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69060-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:02:30Z","timestamp":1772812950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69060-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69060"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69060-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2272"}}